Prime Medicine Inc (PRME) Stock Price, Quote & News

Company Profile

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and peg...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 465 0013

Website: primemedicine.com

Address:

60 First Street, Cambridge, United States

WillyBoyQc Feb. 3 at 9:09 PM

$PRME As written

0 · Reply

FredGS Feb. 3 at 9:06 PM

$PRME Maybe this is the last time we hit the $3.50's

1 · Reply

PorkchopSquats Feb. 3 at 8:16 PM

$PRME That wick off the 200MA.

0 · Reply

TooPoorForPennyStocks Feb. 3 at 7:58 PM

$PRME @arg195 You can't make this shit up lmfao perfect timing.

1 · Reply

Elamenape2 Feb. 3 at 7:58 PM

$PRME $BEAM $NTLA $CRSP Rare Pediatric Disease PRV Program Reauthorized by Congress! After a two-year campaign to reauthorize the Rare Pediatric Disease Priority Review Voucher (PRV) Program, the rare disease community's relentless advocacy has paid off. https://abcnews.go.com/Politics/house-hold-votes-funding-end-partial-government-shutdown/story?id=129813498

0 · Reply

WillyBoyQc Feb. 3 at 6:32 PM

$PRME Gotta hold here

1 · Reply

arg195 Feb. 3 at 6:29 PM

$PRME offering price 🧲🧲🧲

0 · Reply

APman Feb. 3 at 5:42 PM

$PRME Meh. Near bottom. Picked up 20k. Sold some NTLA. I was too concentrated in NTLA. Figure both will trade same direction but I think PRME is better for long term.

1 · Reply

Elamenape2 Feb. 3 at 5:34 PM

$PRME

0 · Reply

someguytrades Feb. 3 at 5:34 PM

$PRME breaking down

1 · Reply

Prime Medicine, Inc. (PRME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 7, 2026, 8:00 AM EST - 27 days ago

Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 31, 2025, 1:29 PM EST - 4 weeks ago

Prime: Maintaining 'Buy' On Solidified Catalysts For Wilson's Disease And Beyond

Dec 7, 2025, 8:05 AM EST - 2 months ago

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

Nov 25, 2025, 8:00 AM EST - 2 months ago

Prime Medicine to Present at 8th Annual Evercore Healthcare Conference

Nov 12, 2025, 2:51 PM EST - 2 months ago

Prime Medicine, Inc. (PRME) Discusses Liver Disease Franchise Strategy With Focus on Wilson Disease Transcript

Nov 11, 2025, 8:00 AM EST - 3 months ago

Prime Medicine to Present at Jefferies Global Healthcare Conference

Nov 7, 2025, 10:21 AM EST - 3 months ago

CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 7, 2025, 7:00 AM EST - 3 months ago

Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 3, 2025, 8:01 AM EST - 3 months ago

Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer

Oct 30, 2025, 4:01 PM EDT - 3 months ago

Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy

Oct 7, 2025, 8:00 AM EDT - 4 months ago

Prime Medicine to Participate in Upcoming Investor Conferences

Sep 8, 2025, 5:38 PM EDT - 5 months ago

Prime Medicine, Inc. (PRME) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 2, 2025, 8:07 PM EDT - 5 months ago

Prime Medicine, Inc. (PRME) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 7, 2025, 8:00 AM EDT - 6 months ago

Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 1, 2025, 4:01 PM EDT - 6 months ago

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Jul 30, 2025, 9:33 PM EDT - 6 months ago

Prime Medicine Announces Pricing of Public Offering

Jul 30, 2025, 4:01 PM EDT - 6 months ago

Prime Medicine Announces Proposed Public Offering of Common Stock

Jul 16, 2025, 8:10 AM EDT - 7 months ago

Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy

Jul 16, 2025, 7:00 AM EDT - 7 months ago

Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis

Jul 7, 2025, 4:45 PM EDT - 7 months ago

Prime Medicine: Pressing Forward With Lead Liver Targeting Indications

May 19, 2025, 8:31 AM EDT - 9 months ago

Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

May 19, 2025, 8:30 AM EDT - 9 months ago

Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease

May 8, 2025, 8:00 AM EDT - 9 months ago

Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates

Mar 18, 2025, 7:00 AM EDT - 11 months ago

Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Feb 28, 2025, 8:00 AM EST - 1 year ago

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

Feb 24, 2025, 8:00 AM EST - 1 year ago

Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference

Jan 30, 2025, 12:26 PM EST - 1 year ago

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm

Nov 26, 2024, 5:10 AM EST - 1 year ago

Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies

BMY

Nov 21, 2024, 4:18 AM EST - 1 year ago

Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings

Sep 30, 2024, 12:17 PM EDT - 1 year ago

Crude Oil Moves Higher; Prime Medicine Shares Spike Higher

Sep 30, 2024, 8:38 AM EDT - 1 year ago

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline

BMY

Sep 30, 2024, 7:01 AM EDT - 1 year ago

Prime Medicine Unveils Strategically Focused Pipeline

May 13, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 12, 2024, 3:00 AM EDT - 1 year ago

Alphabet Bought Up Two Slumping Stocks

GOOG GOOGL GTLB

May 10, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

May 8, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

Apr 29, 2024, 7:00 AM EDT - 1 year ago

Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

Mar 1, 2024, 8:00 AM EST - 2 years ago

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

Feb 20, 2024, 4:01 PM EST - 2 years ago

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Feb 14, 2024, 11:50 PM EST - 2 years ago

Prime Medicine Announces Pricing of Upsized Public Offering

Jan 28, 2024, 8:11 AM EST - 2 years ago

Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing

Jan 25, 2024, 8:00 AM EST - 2 years ago

Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis

Jan 25, 2024, 8:00 AM EST - 2 years ago

Cystic Fibrosis Foundation Funds Up to $15 Million to Prime Medicine to Pursue Gene Editing in CF

Jan 5, 2024, 8:00 AM EST - 2 years ago

Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer

Jan 2, 2024, 8:00 AM EST - 2 years ago

Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference

Dec 1, 2023, 2:45 PM EST - 2 years ago

AI In Biotech: A Revolutionary Leap Forward Or Just Another Buzzword?

CRSP

WillyBoyQc Feb. 3 at 9:09 PM

$PRME As written

0 · Reply

FredGS Feb. 3 at 9:06 PM

$PRME Maybe this is the last time we hit the $3.50's

1 · Reply

PorkchopSquats Feb. 3 at 8:16 PM

$PRME That wick off the 200MA.

0 · Reply

TooPoorForPennyStocks Feb. 3 at 7:58 PM

$PRME @arg195 You can't make this shit up lmfao perfect timing.

1 · Reply

Elamenape2 Feb. 3 at 7:58 PM

0 · Reply

WillyBoyQc Feb. 3 at 6:32 PM

$PRME Gotta hold here

1 · Reply

arg195 Feb. 3 at 6:29 PM

$PRME offering price 🧲🧲🧲

0 · Reply

APman Feb. 3 at 5:42 PM

$PRME Meh. Near bottom. Picked up 20k. Sold some NTLA. I was too concentrated in NTLA. Figure both will trade same direction but I think PRME is better for long term.

1 · Reply

Elamenape2 Feb. 3 at 5:34 PM

$PRME

0 · Reply

someguytrades Feb. 3 at 5:34 PM

$PRME breaking down

1 · Reply

PorkchopSquats Feb. 3 at 5:18 PM

$PRME 10% swing in price on under the 800k shares traded. On pace for the lowest volume day since June. Need news and volume, until the it will just continue to drift aimlessly.

0 · Reply

TooPoorForPennyStocks Feb. 3 at 4:25 PM

$PRME So many wrong predictions, its not even worth pointing them all out. Gonna bark all day little doggy, or are you gonna bite?

1 · Reply

PorkchopSquats Feb. 3 at 4:16 PM

$PRME Looks like this is just gonna chop indefinitely until something is announced. Keep making higher lows over the past 8 months, but can’t reliably stay over $4. Continue to watch the daily 200MA (currently at $3.56), so long as that is holding strong it’s all noise.

2 · Reply

Mcnulty_jimmy Feb. 3 at 3:03 PM

$PRME Daily Deion

0 · Reply

arg195 Feb. 3 at 3:00 PM

$PRME red again and pumpers back in hiding. Next stop offering price

0 · Reply

someguytrades Feb. 3 at 2:55 PM

$PRME doesn’t help that most of the people pumping prime are also pumping scam cos like Ionq and oklo

0 · Reply

ElRaydelRiO13 Feb. 3 at 4:11 AM

$PRME $GOOG

0 · Reply

Elamenape2 Feb. 2 at 9:38 PM

$PRME The consistency is remarkable 🫡

0 · Reply

someguytrades Feb. 2 at 9:07 PM

$PRME it did not hold and ended the day like the rest of the garbage 🙄 time is running out to decouple before tech makes significant correction

0 · Reply

arg195 Feb. 2 at 8:54 PM

$PRME offering price like a magnet 🧲

0 · Reply

603stockgoat Feb. 2 at 4:33 PM

$PRME it’s prime time baby

1 · Reply

someguytrades Feb. 2 at 3:49 PM

$PRME finally decoupling from the garbage. We’ll see if it holds

1 · Reply

Market Cap	687.75M
Revenue (ttm)	2.98M
Net Income (ttm)	-195.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6,573.15%
Debt to Equity Ratio	0.00

Volume	2,779,200
Avg Vol	3,456,420
Day's Range	N/A - N/A
Shares Out	180.51M
Stochastic %K	23%
Beta	2.71
Analysts	Strong Sell
Price Target	$6.46